FinSei Ltd Partners with FinHub.cloud to Accelerate Next-Generation Payment Solutions Across the UK and Europe

FinSei (previously AltPay.uk), an innovative fintech company specializing in secure, seamless payment services, has announced a strategic partnership with FinHub.cloud, a global leader in cloud-based financial infrastructure. This collaboration will boost FinSei's scalability, security, and operational efficiency across the UK and Europe. https://mma.prnewswire.com/media/2724301/FinHub_Partnership.jpg About FinSei FinSei delivers compliant, technology-driven financial services for businesses and consumers. […]

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist

Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist GlobeNewswire July 04, 2025 Tokyo, Japan and Cambridge, UK, 4 July 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it will receive US$4.8 million

Smartee Chief Scientist Appointed Full Professor at Italy’s Historic University of Padua

Smartee Denti-Technology Forms Landmark Academic Partnership with 800-Year-Old European Institution The University of Padua, Italy's second-oldest and one of the world's top-five oldest universities, has appointed Prof. Gang Shen-Chief Scientist of R&D at Smartee Denti-Technology, Executive President of TaiKang Dental-as Full Professor of Orthodontics. The appointment honors Prof. Shen's pioneering work on Smartee's Mandibular Repositioning

Bridge Data Centres Unveils Inaugural ESG Report, Outlines Vision for a Sustainable Digital Future

— Significant advances in innovative cooling technologies in past year lowered power usage effectiveness (PUE) in subtropical regions to below 1.2 — Report details six environmental performance domains – water resources management, high-efficiency thermal management, energy system resilience, carbonfootprint reduction, green technology R&D, and digital energy governance Bridge Data Centres, aBain Capital-backed hyperscale data centre

Invitation to presentation of Electrolux Group Q2 report

On 18thof July, Electrolux Group will publish the results for the second quarter of 2025, at approx. 07.00 CET. Media, investors and analysts are invited to a simultaneous video webcast and telephone conference on the same day following the release of the results, starting at 09.00 CET where Yannick Fierling, President and CEO, together with

Ping An Good Doctor Selected for First Batch of “Open-Source LLMs+” Innovation Application Cases, Showcasing Medical AI Scenario Implementation

The “Global Digital Economy Conference – Cloud-Intelligence-Computing Security Forum,” also known as the third “SecGo Security Forum,” was successfully held today in Beijing. The event was organized by the Global Digital Economy Conference Organizing Committee and co-hosted by the China Academy of Information and Communications Technology (“CAICT”) and the China Communications Standards Association. During the

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

(Paris:AB), PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING POPULATION MOST LIKELY TO BENEFIT Paris, July 4, 2025, 8am CET AB Science SA (Euronext – FR0010557264 – AB) today announced that a confirmatory phase 3 trial of masitinib in metastatic

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer GlobeNewswire July 04, 2025 PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIENT SELECTION TARGETING POPULATION MOST LIKELY TO BENEFIT Paris, July 4, 2025, 8am

Touchstone Exploration Inc. Announces Employee Share Purchase Plan & PDMR Purchases

CALGARY, AB / ACCESS Newswire / July 4, 2025 / Touchstone Exploration Inc. ("Touchstone" or the "Company") (TSX:TXP)(LSE:TXP) announces the following purchases under its Employee and Non-Executive Director Share Purchase Plan. 1 Details of the person discharging managerial responsibilities / person closely associated a) Name 1. Paul R. Baay 2. Scott Budau 3. Brian Hollingshead

Scroll to Top